<DOC>
	<DOCNO>NCT01082094</DOCNO>
	<brief_summary>The purpose Phase 1 study ass safety , tolerability , preliminary efficacy single escalate dos ACRX-100 deliver via endomyocardial injection adult ischemic heart failure .</brief_summary>
	<brief_title>Study Evaluate Safety Single Escalating Dose ACRX-100 Adults With Ischemic Heart Failure</brief_title>
	<detailed_description>This open label , 16 subject , Phase 1 dose-escalation study demonstrate initial safety use ACRX-100 treat heart failure subject ischemic cardiomyopathy . Safety track dose document adverse event ( AEs ) , primary safety endpoint number major cardiac AEs 30 day . In cohort ( n=4 low dose , n=6 mid high dose ) , subject receive single dose ACRX-100 . Preliminary efficacy evaluate measuring impact cardiac function via standard echocardiography measurement , cardiac perfusion via SPECT imaging , improvement NYHA classification .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Greater equal 18 year age NYHA Class III Ischemic cardiomyopathy without acute coronary syndrome within last 6 month Residual welldemarcated region LV systolic dysfunction define least 3 consecutive segment abnormal wall motion echocardiography read echocardiography core laboratory LVEF le equal 40 % measure echocardiography read echocardiography core laboratory No leave ventricular wall thickness le 0.5 cm measure echocardiography read echocardiography core laboratory Mitral regurgitation 02+ ( inclusive ) measure echocardiography read echocardiography core laboratory Subject implant , functional AICD Subject receive stable optimal pharmacological therapy define : ACE inhibitor and/or ARB , Betablocker 90 day stable dose 30 day unless contraindicate Diuretic subject evidence fluid retention ASA unless contraindicate Statin unless contraindicate Aldosterone antagonist per physician discretion unless contraindicate Subjects find diagnosis diabetes must ophthalmologist exam within last year show active proliferative retinopathy Planned revascularization within 30 day follow enrollment Estimated Glomerular Filtration Rate &lt; 30 ml/min* Inability undergo SPECT image History aortic valve regurgitation &gt; 2 Moderate/Severe aortic stenosis define AVA &lt; 1.5 cm2 Presence artificial aortic valve Subjects aortic aneurysm &gt; 3.8 cm History cancer exception basal cell carcinoma follow result age appropriate cancer screening Subjects persistent atrial fibrillation ( per ACC/AHA/ESC guideline , define recurrent AF episodes lasting longer 7 day ) Subjects Biventricular pace device implant within last 3 month OR previously implant Biventricular pace device programming plan reoptimized follow enrollment trial Previous solid organ transplant Subjects great 40 % univentricular RV Pacing Subjects uncontrolled diabetes define HbA1c &gt; 9.0 % Participation experimental clinical trial within 30 day prior enrollment Life expectancy less 1 year Positive pregnancy test ( serum Î²HCG ) woman childbearing potential and/or unwillingness use contraceptives limit sexual activity Unwillingness men capable father child agree use barrier contraception limit sexual activity Subjects breast feeding Subjects positive test result hepatitis B/C and/or HIV Total Serum Bilirubin &gt; 4.0 mg/dl Aspartate aminotransferase ( AST ) &gt; 120 IU/L Alanine aminotransferase ( ALT ) &gt; 135 IU/L Alkaline phosphatase ( ALP ) : &gt; 300 IU/L Clinically significant elevation PT PTT relative laboratory norm Proteinuria &gt; 3.5 g/L Any subject know exist LV thrombus LV thrombus detect screening period study . Presence LV thrombus determine echocardiography addition echocontrast question remain noncontrast echocardiogram . History drug alcohol abuse within last year A subject exclude he/she unfit trial base discretion site Principal Investigator Estimated Glomerular Filtration Rate ( eGFR ) ml/min calculate use subject 's serum creatinine value follow equation : eGFR = 186 x ( serum creatinine mg/dl ) 1.154 x ( Age ) .2303 x ( Age ) x ( 1.210 subject black ) x ( 0.742 subject female )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Ischemic heart failure</keyword>
	<keyword>Congestive heart failure</keyword>
	<keyword>Stromal cell-derived factor 1</keyword>
	<keyword>SDF-1</keyword>
	<keyword>Gene therapy</keyword>
</DOC>